Interleukin 17 receptor in multiple sclerosis patients treated with interferon β-1a

被引:0
|
作者
Michalowska-Wender, Grazyna [1 ,2 ]
Biernacka-Lukanty, Justyna [2 ]
Lasik, Zofia [2 ]
Jernas, Lukasz
Wender, Mieczyslaw [1 ]
机构
[1] Polish Acad Sci, Mossakowski Med Res Ctr, Neuroimmunol Unit, PL-60533 Poznan, Poland
[2] Med Univ Poznan, Dept Neurol, Neurogenet Lab, Poznan, Poland
关键词
interleukin; 17; multiple sclerosis; interferon beta-1a; MONONUCLEAR-CELLS; BLOOD;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Interleukin 17 (IL-17) and its receptor IL-17R1 produced by T-helper cells named Th17 are involved in the pathology of autoimmune diseases. In contrast to the at least partially explained role of IL-17 in pathology of multiple sclerosis, the significance of IL-17R in MS is unclear Therefore we have studied the expression of IL-17R in the stable phase of multiple sclerosis treated by interferon beta-1a. The studied material consisted of 20 MS patients with relapsing-remitting form of the disease, and fulfilling the diagnostic McDonald et al. criteria. The patients were treated subcutaneously every second day with 30 mg of interferon beta-1a (Betaferon). The interleukin 17 receptor level was measured by the ELISA immunoassay test using RayBio human IL-17R ELISA kit. After three months of therapy with interferon beta-1a the level of IL-17R was significantly higher than that established at the starting point. The level of IL-17R after 6 months of therapy was insignificantly higher than established in the previous study group (3 months of therapy). While it remains difficult to pinpoint the exact significance of upregulation of IL-17R in the early period of therapy, the present findings should be taken into account when considering the pharmacodynamics of interferon action in MS in view of the opinions on the crucial role of IL-17 in pathology of MS and suggestions that it may constitute a drug target in autoimmunological diseases.
引用
收藏
页码:138 / 141
页数:4
相关论文
共 50 条
  • [1] A preliminary metabolomic study of patients with multiple sclerosis treated with interferon β 1a
    Cocco, E.
    Lorefice, L.
    Murgia, F.
    Barberini, L.
    Frau, J.
    Fenu, G.
    Coghe, G.
    Melis, M.
    Murru, M. R.
    Murru, R.
    Poddighe, S.
    Atzori, L.
    Marrosu, M. G.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 264 - 264
  • [2] Modulation of interleukin-16 by interferon β-1a treatment in patients with multiple sclerosis
    Nischwitz, S.
    Saemann, P. G.
    Knop, M.
    Mueller-Sarnowski, F.
    Faber, H.
    Yassouridis, A.
    Weber, F.
    JOURNAL OF NEUROLOGY, 2010, 257 : S218 - S219
  • [3] Evaluation of the risk of malignancy in patients with multiple sclerosis treated with subcutaneous interferon β-1a
    Sandberg-Wollheim, M.
    Kornmann, G.
    Moraga, M.
    Miret, M.
    Alteri, E.
    JOURNAL OF NEUROLOGY, 2010, 257 : S10 - S10
  • [4] Affinity maturation of antibodies against interferon-β in patients with multiple sclerosis treated with interferon β-1a
    Basuroski, I. Dujmovic
    Deisenhammer, F.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S244 - S245
  • [5] Nephrotic syndrome in a multiple sclerosis patient treated with interferon β1a
    Auty, A
    Saleh, A
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2005, 32 (03) : 366 - 368
  • [6] Serum auto antibodies presence in multiple sclerosis patients treated with ß-interferon 1a and 1b
    Speciale, L
    Saresella, M
    Caputo, D
    Ruzzante, S
    Mancuso, R
    Calvo, MG
    Guerini, FR
    Ferrante, P
    JOURNAL OF NEUROVIROLOGY, 2000, 6 : S57 - S61
  • [7] Clinical characterisation of interferon inhibitory activity in multiple sclerosis patients treated with IFN-β-1a
    Weinstock-Guttman, B.
    Ramanathan, M.
    Zivadinov, R.
    Khan, A.
    Dillon, M.
    Patrick, K.
    Masud, M. W.
    Hojnacki, D.
    Chadha, K.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 501 - 502
  • [8] Risk of Stroke in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon beta-1a (scIFNβ-1a)
    Sabido, Meritxell
    Venkatesh, Saritha
    Aldridge, Julie
    Gillett, Alan
    NEUROLOGY, 2018, 90
  • [9] Economic comparison or interferon β-1a and natalizumab in patients with multiple sclerosis
    Joyeux, A.
    Kozma, C.
    Dickson, M.
    Meletiche, D.
    Bennett, R.
    JOURNAL OF NEUROLOGY, 2009, 256 : S163 - S163
  • [10] Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in Multiple Sclerosis Patients Treated with Interferon β-1a
    Rahimi, Mahnoosh
    Afjeh, Sarah Saadat Aghabozorg
    Omrani, Mir Davood
    Arsang-Jang, Shahram
    Ganji, Maziar
    Noroozi, Rezvan
    Taheri, Mohammad
    Ghafouri-Fard, Soudeh
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 46 (02) : 561 - 567